| |
Evidence, Appropriateness, And Technology Assessment In Cardiology: A Case Study Of Computed Tomography
Rita F. Redberg
As the volume, complexity, and cost of new medical technology increase, the need for evaluating benefits and risks becomes increasingly important. Once the formal requirements for Food and Drug Administration approval and insurance coverage are met, however, few systematic criteria are applied to ensure patient benefit. A more systematic policy approach regarding new technologies is needed, with input from balanced groups reviewing evidence of clinical outcomes data to determine patient benefit. This paper examines cardiac computed tomography angiography as a case study; it proposes procedures designed to ensure that the benefits of new technologies justify their costs.

What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Hachamovitch and M. F. Di Carli
Methods and Limitations of Assessing New Noninvasive Tests: Part I: Anatomy-Based Validation of Noninvasive Testing
Circulation,
May 20, 2008;
117(20):
2684 - 2690.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. S. Douglas, M. Budoff, S. Tunis, P. K. Woodard, R. A. Justman, and R. Honigberg
A New Era for Cardiovascular Imaging? Implications of the Revoked National Coverage Decision for CT Angiography on Future Imaging Reimbursement
J. Am. Coll. Cardiol. Img.,
May 1, 2008;
1(3):
398 - 403.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Gerber, B. Kantor, and P. Chareonthaitawee
Coronary computed tomographic angiography and exercise electrocardiography: a great match or unequal partners?
Eur. Heart J.,
August 1, 2007;
28(15):
1787 - 1789.
[Full Text]
[PDF]
|
 |
|
|